IMR Press / FBL / Volume 24 / Issue 5 / DOI: 10.2741/4756

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Higenamine alleviates cerebral ischemia-reperfusion injury in rats
Show Less
1 Department of Neurology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Sichuan, 610072, China
2 Department of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Sichuan, 610072, China
3 Hyperbaric oxygen therapy center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Sichuan, 610072, China
Front. Biosci. (Landmark Ed) 2019, 24(5), 859–869; https://doi.org/10.2741/4756
Published: 1 March 2019
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)
Abstract

Cerebral ischemia reperfusion (I/R) injury is associated with a high incidence of neurological morbidity and mortality worldwide. Higenamine has anti-inflammatory, anti-oxidative and anti-apoptotic capacities and has been successfully used in myocardial and intestinal ischemia reperfusion. We hypothesized that higenamine might serve the same effects in cerebral I/R. In a rat model of cerebral I/R, higenamine improved functional state of nerves, significantly inhibited the I/R-induced increase in the serum level of tumor necrosis factor α (TNF-alpha) and interleukins (ILs) such as IL-1, IL-6 and IL-18, and CD14+ cells, while decreasing the axonal nerve degeneration. Together, the data demonstrate that higenamine has therapeutic effect in cerebral I/R injury.

Keywords
Higenamine
Cerebral I/R
BBB
Axonal regeneration
Inflammatory response
Figures
Figure 1
Share
Back to top